Initial prioritization considerations for new gene/drug pair (may change over time as evidence and experience accumulates) New Gene/drug pair Gene already subject to CPIC guideline Priority 1 Gene not yet subject to CPIC guideline Actionable in Dutch or other professional society guidelines Priority 2 Nominated by CPIC member or outside advocate like FDA labeling Priority 3 PharmGKB Annotation level 1A, 1B, 2A or 2B Priority 4 Mentioned in professional society guidelines but not actionable Priority 5 Evaluate alternatives, evidence Evaluate alternatives, evidence, degree of testing PharmGKB annotation only: no prescribing action recommended; alternatives unclear or evidence is weak; testing is rare or nonexistent CPIC guideline: prescribing action recommended; alternative therapies or dosing are highly likely to be effective and safe CPIC evaluation: no prescribing action recommended; alternatives are unclear, but testing is common